Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000451 · ClinicalTrials.gov registry record · Phase 2
Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)
A Phase 2 study of Alcoholism and Alcohol Dependence, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 198
- Enrollment target
- 1
- Study location
NCT00000451 is a Phase 2 study of Alcoholism and Alcohol Dependence that has completed, run by Yale University. The registered enrollment target is 198 participants, below the 372-participant average among 65 other Alcoholism trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00000451, a Phase 2 study of Alcoholism and Alcohol Dependence, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 198 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individuals will be recruited into a 16 week outpatient study.
Conditions Studied
Interventions
- DRUG sertraline
- DRUG naltrexone
Study Locations (1)
Connecticut
- - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2003-01 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000451
The ClinicalTrials.gov registry entry for NCT00000451 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 372-participant average among 65 other Alcoholism trials with a reported enrollment target (47% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alcoholism appearing as the primary indexed condition, and to 2 interventions - of which sertraline is the first listed.
NCT00000451 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00000451 about?
NCT00000451 is a clinical study titled "Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)". This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individua...
What is the current status of trial NCT00000451?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 198 participants. The study started on 2003-01. Estimated completion is 2005-11.
What conditions does trial NCT00000451 study?
This clinical trial studies the following conditions: Alcoholism, Alcohol Dependence.
What interventions are being tested in trial NCT00000451?
The interventions under investigation include: sertraline (DRUG), naltrexone (DRUG).
Who is sponsoring clinical trial NCT00000451?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000451 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ketamine Alcohol (in Treatment-Resistant Depression)
RECRUITING · Phase 2
-
Ibudilast for Treating Alcohol Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Gabapentin Treatment of Alcohol Dependence
COMPLETED · Phase 2
-
A Study of LY2940094 in Participants With Alcohol Dependency
COMPLETED · Phase 2
-
Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients
COMPLETED · Phase 2
-
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.